文献速递糖尿病

2000-2022年美国成人糖尿病患者降糖药自付费用全国趋势

National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000-2022.
PubMed 文献 · Diabetes Care · 2026-01-01

该研究分析2000至2022年医学支出面板调查数据,评估美国成人糖尿病患者降糖药物自付费用的全国趋势。结果显示人均自付费用下降46%,主要由较老口服药人均自付费用大幅降低和人体胰岛素使用减少驱动;但新型药物和类似物胰岛素的自付费用仍较高且使用激增,各亚组间差异持续存在。

要点

  • 人均降糖药自付费用下降46%,但新型药物和类似物胰岛素费用仍高。
  • 较老口服药人均自付费用大幅降低和人体胰岛素使用减少是费用下降主因。
  • 各亚组自付费用均有下降,但亚组间差异仍然存在。

核心结论

  • 尽管总体自付费用大幅下降,高费用新型疗法仍造成经济负担,可能限制公平可及性。

研究设计与样本

  • 研究分析医学支出面板调查数据,链接药房核实记录,纳入自报糖尿病的成人。
  • 按药物类别评估每位使用者自付费用,并在人群水平评估。
  • 采用通胀调整年估计和连接点回归评估趋势,并按收入、种族和民族、年龄、保险、胰岛素使用和心血管疾病状态进行亚组分析。

主要发现

  • 人群平均自付费用下降46%,由较老口服药每位使用者自付费用大幅降低和人体胰岛素使用减少驱动。
  • 新型药物和类似物胰岛素的自付费用仍较高,且使用激增。
  • 所有亚组自付费用均下降,但亚组间差异仍存在。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To examine national trends in out-of-pocket (OOP) costs for glucose-lowering medications among U.S. adults with diabetes from 2000 to 2022. RESEARCH DESIGN AND METHODS: We analyzed Medical Expenditure Panel Survey data, linked to pharmacy-verified records, for adults with self-reported diabetes. OOP costs were evaluated per user by medication category and at the population level. Trends were assessed using inflation-adjusted annual estimates and joinpoint regression, with subgroup analyses by income, race and ethnicity, age, insurance, insulin use, and cardiovascular disease status. RESULTS: Population-average OOP costs declined 46%, driven by sharp per-user OOP cost reductions for older oral agents and decreasing use of human insulin. OOP costs for newer agents and analog insulin remained higher, with surging uptake. Declines occurred across all subgroups, but differences between subgroups were still observed. CONCLUSIONS: Despite substantial reductions in overall OOP costs, high-cost newer therapies continue to impose financial burdens that may limit equitable access.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Wang Y, Tang S, Zhou X, et al. National Trends in Out-of-Pocket Cost for Glucose-Lowering Drugs Among U.S. Adults With Diabetes, 2000-2022. Diabetes Care. 2026. PMID: 42301155. doi:10.2337/dc25-2040

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。